T
Tara Maddala
Researcher at Bristol-Myers Squibb
Publications - 53
Citations - 2208
Tara Maddala is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 17, co-authored 48 publications receiving 1686 citations. Previous affiliations of Tara Maddala include Mayo Clinic.
Papers
More filters
Journal ArticleDOI
A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling
Eric A. Klein,Matthew R. Cooperberg,Cristina Magi-Galluzzi,Jeffry P. Simko,Sara M. Falzarano,Tara Maddala,June M. Chan,Jianbo Li,Janet E. Cowan,Athanasios C. Tsiatis,Diana B. Cherbavaz,Robert J. Pelham,Imelda Tenggara-Hunter,Frederick L. Baehner,Dejan Knezevic,Phillip G. Febbo,Steven Shak,Michael W. Kattan,Mark Lee,Peter R. Carroll +19 more
TL;DR: GPS was validated for its ability to predict men who have high-grade or high-stage PCa at diagnosis and may help men diagnosed with PCa decide between active surveillance and immediate definitive treatment.
Journal ArticleDOI
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Pedram Razavi,Bob T. Li,David N Brown,Byoungsok Jung,Earl Hubbell,Ronglai Shen,Wassim Abida,Krishna Juluru,Ino de Bruijn,Chenlu Hou,Oliver Venn,Raymond S. Lim,Aseem Anand,Tara Maddala,Sante Gnerre,Ravi Vijaya Satya,Qinwen Liu,Ling Shen,Nicholas Eattock,Jeanne Yue,Alexander W. Blocker,Mark Lee,Amy J. Sehnert,Hui Xu,Megan P. Hall,Angie Santiago-Zayas,William Novotny,James M. Isbell,Valerie W. Rusch,George Plitas,Alexandra S. Heerdt,Marc Ladanyi,David M. Hyman,David R. Jones,Monica Morrow,Gregory J. Riely,Howard I. Scher,Charles M. Rudin,Mark E. Robson,Luis A. Diaz,David B. Solit,Alex Aravanis,Jorge S. Reis-Filho +42 more
TL;DR: Ultra-sensitive cell-free DNA (cfDNA) sequencing uncovers clonal hematopoiesis as a major source of somatic cfDNA variants in healthy individuals and patients with cancer, and underscores the importance of matched white blood cell DNA sequencing in liquid biopsy procedures.
Journal ArticleDOI
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: Development and validation studies
Brian I. Rini,Audrey Goddard,Dejan Knezevic,Tara Maddala,Ming Zhou,Hakan Aydin,Steven C. Campbell,Paul Elson,Serge Koscielny,Margarita Lopatin,Christer Svedman,Jean-Francois Martini,J. Andrew Williams,Virginie Verkarre,Camelia Radulescu,Yann Neuzillet,Isabelle Hemmerle,Marc Olivier Timsit,Athanasios C. Tsiatis,Michael Bonham,Thierry Lebret,Arnaud Mejean,Bernard Escudier +22 more
TL;DR: The findings validate the recurrence score as a predictor of clinical outcome in patients with stage I-III clear cell renal cell carcinoma, providing a more accurate and individualised risk assessment beyond existing clinical and pathological parameters.
Journal ArticleDOI
Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory
Sunil Badve,Frederick L. Baehner,Robert Gray,Barrett H. Childs,Tara Maddala,Mei Lan Liu,Steve Rowley,Steven Shak,Edith D. Perez,Lawrence J. Shulman,Silvana Martino,Nancy E. Davidson,GW Sledge,Lori J. Goldstein,Joseph A. Sparano +14 more
TL;DR: Although ER expression is marginally associated with relapse in ER-positive patients treated with chemohormonal therapy, recurrence score is a highly significant predictor of recurrence.
Journal ArticleDOI
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
Frederick L. Baehner,Ninah Achacoso,Tara Maddala,S. Shak,Charles P. Quesenberry,Lynn C. Goldstein,Allen M. Gown,Laurel A. Habel +7 more
TL;DR: There is a high degree of concordance between central FISH and quantitative RT-PCR using Oncotype DX for HER2 status, and the assay warrants additional study in a trastuzumab-treated population.